$242.760
-1.845 (-0.76%)At close
DGX News
DGX Events
Quest Diagnostics Launches New Alzheimer's Blood Tests
Quest Diagnostics (DGX) announced two new developments for its Quest AD-Detect portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease. Earlier, Roche (RHHBY) announced that the U.S. FDA has cleared the Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test, making it the first and only FDA-cleared single-assay, single-biomarker blood biomarker test that supports both rule-in and rule-out assessment of amyloid pathology using the same validated clinical cutoffs across primary and specialty care settings. Quest provides a comprehensive menu of blood-based Alzheimer's biomarker tests under the AD-Detect brand name. Quest plans to introduce an AD-Detect-branded laboratory test service based on the FDA-cleared Elecsys pTau217 assay to physicians and clinical trials collaborators nationwide in the fourth quarter of this year. Quest also plans to incorporate the Roche test in future AD-Detect panels in 2027. Separate from the FDA clearance of the Roche pTau217 test, Quest also announced it will launch its newest AD-Detect test innovation, AD-Detect ABeta 42/40, p-tau217, and ApoE Evaluation, lab-developed test for physicians and clinical trials collaborators nationwide at the end of this month. The test provides a score predicting the likelihood of Alzheimer's pathology based on results of pTau217 using a third party in vitro diagnostic as well as results of amyloid beta 42/40 and the APOE isoform using Quest's highly sensitive mass spectrometry method.
Notable Gainers This Morning Include United Rentals and Others
Notable gainers among liquid option names this morning include United Rentals (URI) $1170.47 +135.41, Lockheed (LMT) $573.42 +59.06, Allegion (ALLE) $155.47 +15.53, Quest Diagnostics (DGX) $231.59 +21.75, and Thermo Fisher (TMO) $580.31 +53.85.
Dow, S&P 500, and Nasdaq Futures Decline
Stock futures are lower as investors digest the first wave of megacap technology earnings, with concerns over accelerating artificial intelligence spending outweighing otherwise solid quarterly results. Dow, S&P 500 and Nasdaq futures are all in negative territory before the opening bell, while Treasury yields and oil prices are climbing, adding pressure to equity markets.Alphabet and Tesla set the tone for the session after reporting second quarter results late Wednesday. Alphabet posted record growth in its cloud business and topped earnings expectations, but investors focused on the company's increased capital expenditure outlook as it ramps up AI investments. Tesla also came under pressure after reporting negative free cash flow for the first time in more than two years, reinforcing concerns about margins and the cost of its AI and autonomous driving initiatives.The market's attention has shifted from whether big tech can deliver earnings growth to whether the billions of dollars being poured into AI infrastructure will generate sufficient returns. Investors will continue to monitor upcoming results from Intel and other technology companies for additional insight into AI-related capital spending and demand across the semiconductor supply chain.Geopolitical tensions are also weighing on sentiment after attacks linked to Iranian-backed Houthi militants disrupted shipping near the Bab el-Mandeb strait. Brent crude has climbed toward $100 a barrel, raising fresh concerns about inflation. Higher oil prices have pushed Treasury yields higher, particularly on the short end of the curve.In pre-market trading, S&P 500 futures fell 0.98%, Nasdaq futures fell 1.37% and Dow futures fell 1.0%.Check out this morning's top movers from around Wall Street, compiled by The Fly.UP AFTER EARNINGS -Cleveland-Cliffsup 9%West Pharmaceuticalsup 7%Quest Diagnosticsup 6%RTXup 5%Lockheed Martinup 5%Thermo Fisherup 5%Huntington Bancsharesup 1%Tractor Supplyup 4%McCormickup 1%Nokiaup 1%Honeywellup 1%DOWN AFTER EARNINGS -Alphabetdown 5%STMicroelectronicsdown 13%Tesladown 7%American Airlinesdown 5%Infosysdown 4%T-Mobiledown 4%Dow Inc.down 2%Harley-Davidsondown 1%
Raises FY26 Revenue Outlook to $11.95B-$12.05B
Consensus $10.77. Raises FY26 revenue view to $11.95B-$12.05B from $11.78B-$11.9B, consensus $11.85B. Backs FY26 capital expenditures view $550M.
Company Reports Q2 Revenue of $3.04B, Exceeds Expectations
Reports Q2 revenue $3.04B, consensus $2.97B. "Our robust top- and bottom-line growth in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights that illuminate paths for better health," said Jim Davis, Chairman, CEO and President. "Revenues increased by over 10%, almost all from organic revenue growth across our physician, hospital and consumer channels, and adjusted diluted EPS grew over 19%. With strong growth and sustained demand for our diagnostic insights, we are again raising our full year guidance."
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。








